Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SGMT Sagimet Biosciences Inc.

Post-Market Trading 01-08 18:54:36 EST

5.37

-0.20

-3.59%

盘后5.39

+0.01+0.28%

18:26 EST

High5.60	Low4.95	Vol2.37M
Open5.54	D1 Closing5.57	Amplitude11.67%
Mkt Cap172.89M	Tradable Cap95.77M	Total Shares32.20M
T/O12.44M	T/O Rate13.31%	Tradable Shares17.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SGMT","market":"US","secType":"STK","nameCN":"Sagimet Biosciences Inc.","latestPrice":5.37,"timestamp":1736370000000,"preClose":5.57,"halted":0,"volume":2373142,"hourTrading":{"tag":"盘后","latestPrice":5.385,"preClose":5.37,"latestTime":"18:26 EST","volume":5220,"amount":27939.40533,"timestamp":1736378787638},"delay":0,"floatShares":17833358,"shares":32195345,"eps":-1.287523,"marketStatus":"Post-Market Trading","change":-0.2,"latestTime":"01-08 18:54:36 EST","open":5.54,"high":5.6,"low":4.95,"amount":12443295.7417848,"amplitude":0.116697,"askPrice":5.61,"askSize":26,"bidPrice":5.15,"bidSize":15,"shortable":0,"etf":0,"ttmEps":-1.287523,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1736384400000},"marketStatusCode":4,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":5.57,"preHourTrading":{"tag":"盘前","latestPrice":5.54,"preClose":5.57,"latestTime":"09:29 EST","volume":14970,"amount":83889.447375,"timestamp":1736346599996},"postHourTrading":{"tag":"盘后","latestPrice":5.385,"preClose":5.37,"latestTime":"18:26 EST","volume":5220,"amount":27939.40533,"timestamp":1736378787638},"volumeRatio":0.980616,"impliedVol":2.0786,"impliedVolPercentile":0.7051},"requestUrl":"/m/hq/s/SGMT/wiki","defaultTab":"wiki","newsList":[{"id":"2501397682","title":"BRIEF-Sagimet Biosciences Announces Oral Presentation At The 9th Annual MASH-TAG 2025 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2501397682","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501397682?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:13","pubTimestamp":1736169197,"startTime":"0","endTime":"0","summary":"BRIEF-Sagimet Biosciences Announces Oral Presentation At The 9th Annual MASH-TAG 2025 ConferenceJan 6  - Sagimet Biosciences Inc SGMT.O:SAGIMET BIOSCIENCES ANNOUNCES ORAL PRESENTATION AT THE 9TH ANNUAL MASH-TAG 2025 CONFERENCESource text: nGNXbV84LfFurther company coverage: SGMT.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA2PYTPM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2501239340","title":"Sagimet Biosciences Announces Oral Presentation at the 9TH Annual Mash-Tag 2025 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2501239340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501239340?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA2PYTPM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2501392032","title":"Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2501392032","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501392032?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168400,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Jan.  06, 2025  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctiona","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/06/3004574/0/en/Sagimet-Biosciences-Announces-Oral-Presentation-at-the-9th-Annual-MASH-TAG-2025-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2491232501","title":"Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2491232501","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491232501?lang=en_us&edition=fundamental","pubTime":"2024-12-15 22:16","pubTimestamp":1734272203,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sgmt/sagimet-biosciences/news/sagimet-biosciences-nasdaqsgmt-is-in-a-good-position-to-deli","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QLD","NQmain","BK4585","LU2095319765.USD","BK4112","PSQ","IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","NVIW.SI","BK4139","QID","USAW.SI",".IXIC","IE00BGHQF748.EUR","NDAQ","SQQQ","SGMT","BK4588","IE00B3QW5Z07.USD","MNQmain","TQQQ","TSYW.SI","LU2210150020.SGD","USJW.SI"],"gpt_icon":1},{"id":"2489781269","title":"Analysts Offer Insights on Healthcare Companies: Chromadex (CDXC) and Sagimet Biosciences, Inc. Class A (SGMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489781269","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489781269?lang=en_us&edition=fundamental","pubTime":"2024-12-08 16:40","pubTimestamp":1733647206,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Chromadex (CDXC – Research Report) and Sagimet Biosc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-chromadex-cdxc-and-sagimet-biosciences-inc-class-a-sgmt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-chromadex-cdxc-and-sagimet-biosciences-inc-class-a-sgmt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4121","BK4137","SGMT","CDXC","BK4139"],"gpt_icon":0},{"id":"2489237474","title":"BUZZ-Sagimet rises as Oppenheimer initiates coverage with 'outperform'","url":"https://stock-news.laohu8.com/highlight/detail?id=2489237474","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489237474?lang=en_us&edition=fundamental","pubTime":"2024-12-07 00:02","pubTimestamp":1733500955,"startTime":"0","endTime":"0","summary":"BUZZ-Sagimet rises as Oppenheimer initiates coverage with 'outperform'** Drug developer Sagimet Biosciences' SGMT.O shares rise 8.4% to $5.05** Oppenheimer starts coverage with \"outperform\" rating and PT at $30 — a 543.8% premium to Thursday's close of $4.66** Brokerage sees \"underappreciated opportunity\" in co's lead experimental drug, denifanstat, being developed to treat metabolic dysfunction-associated steatohepatitis ** MASH is a severe liver disease caused by fat buildup, leading to inflammation and damage** The MASH market is dominated by Madrigal Pharmaceuticals' MDGL.O Rezdiffra** \"We see SGMT as ultimately benefiting from MDGL's build-out of the MASH market as diagnosis rates and reimbursement improve,\" brokerage says ** Oppenheimer expects risk-adjusted peak total revenues of ~$1.9 bln for denifanstat in 2040      ** Including session's move, stock down 8.5% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nL3N3N70WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","MDGL"],"gpt_icon":0},{"id":"2489252350","title":"Oppenheimer Initiates Sagimet Biosciences at Outperform With $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2489252350","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489252350?lang=en_us&edition=fundamental","pubTime":"2024-12-06 21:51","pubTimestamp":1733493115,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $29.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","SGMT"],"gpt_icon":0},{"id":"2489814052","title":"Sagimet Biosciences Initiated at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2489814052","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489814052?lang=en_us&edition=fundamental","pubTime":"2024-12-06 20:27","pubTimestamp":1733488020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 06, 2024 07:27 ET (12:27 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","OPY"],"gpt_icon":0},{"id":"2489247601","title":"Sagimet Biosciences Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2489247601","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489247601?lang=en_us&edition=fundamental","pubTime":"2024-12-06 14:28","pubTimestamp":1733466501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nFWN3N7028:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2489153644","title":"Sagimet Biosciences initiated with an Outperform at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2489153644","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489153644?lang=en_us&edition=fundamental","pubTime":"2024-12-06 05:17","pubTimestamp":1733433443,"startTime":"0","endTime":"0","summary":"Oppenheimer initiated coverage of Sagimet Biosciences (SGMT) with an Outperform rating and $30 price target Published first on TheFly – the ultimat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-initiated-with-an-outperform-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-initiated-with-an-outperform-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","SGMT"],"gpt_icon":0},{"id":"2486183077","title":"Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486183077","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486183077?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:00","pubTimestamp":1732626000,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Nov.  26, 2024  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc.(Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/26/2987446/0/en/Sagimet-Biosciences-to-Participate-in-the-Piper-Sandler-36th-Annual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HCSG","BK4137","SGMT"],"gpt_icon":0},{"id":"2484903475","title":"Sagimet Biosciences participates ik,on No","url":"https://stock-news.laohu8.com/highlight/detail?id=2484903475","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484903475?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:00","pubTimestamp":1732050020,"startTime":"0","endTime":"0","summary":"Biotech Analyst Agrawal holds a conference call with CEO Happel and CFO Chauche on November 22 at 12 pm hosted by Cantor Fitzgerald. ():(https://ca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-participates-ikon-no?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-participates-ikon-no?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GRO","SGMT"],"gpt_icon":0},{"id":"2484962214","title":"Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2484962214","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484962214?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:00","pubTimestamp":1731934800,"startTime":"0","endTime":"0","summary":"Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patients. Both artificial intelligence  and conventional pathology demonstrated denifanstat's strong anti-fibrotic activity. SAN MATEO, Calif., Nov. 18, 2024  -- Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase  inhibitor denifanstat, and preclinical data demonstrating potential benefit of FASN inhibition in atherosclerosis, at the American Association for the Study of Liver Disease  - The Liver Meeting 2024, November 15-19, 2024 in San Diego, California.GLP1 receptor agonist population: 42% denifanstat  vs 0% placebo (n=4) . Type 2 diabetes population: 40% denifanstat  vs 19% placebo  . PNPLA3 I148 carrier population: 30% denifanstat  vs 6% placebo  ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vN9syB.4joRY7zqfsihqcg--~B/aD05NDE7dz0yNTYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/f62671a6941ad62a5569bf4eb2a2514a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vN9syB.4joRY7zqfsihqcg--~B/aD05NDE7dz0yNTYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/f62671a6941ad62a5569bf4eb2a2514a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sagimet-biosciences-presents-clinical-denifanstat-130000389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SHG","SGMT","BK4139","BK4207"],"gpt_icon":0},{"id":"2483584337","title":"Sagimet Biosciences Price Target Maintained With a $32.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483584337","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483584337?lang=en_us&edition=fundamental","pubTime":"2024-11-16 03:46","pubTimestamp":1731699960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 15, 2024 14:46 ET (19:46 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2483092013","title":"Promising Outlook for Sagimet Biosciences: Buy Rating Driven by Denifanstat’s Clinical Success and Phase 3 MASH Program Initiation","url":"https://stock-news.laohu8.com/highlight/detail?id=2483092013","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483092013?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:15","pubTimestamp":1731687310,"startTime":"0","endTime":"0","summary":"Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report) and keeping the price ta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-sagimet-biosciences-buy-rating-driven-by-denifanstats-clinical-success-and-phase-3-mash-program-initiation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-sagimet-biosciences-buy-rating-driven-by-denifanstats-clinical-success-and-phase-3-mash-program-initiation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"gpt_icon":0},{"id":"2483394225","title":"Sagimet Biosciences Advances MASH Treatment with Denifanstat","url":"https://stock-news.laohu8.com/highlight/detail?id=2483394225","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483394225?lang=en_us&edition=fundamental","pubTime":"2024-11-15 12:34","pubTimestamp":1731645291,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences, Inc. Class A ( ($SGMT) ) has released its Q3 earnings. Here is a breakdown of the information Sagimet Biosciences, Inc. Class ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-advances-mash-treatment-with-denifanstat?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-advances-mash-treatment-with-denifanstat?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2483490367","title":"Sagimet Biosciences, Inc.: Strategic Advancements and Financial Robustness Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2483490367","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483490367?lang=en_us&edition=fundamental","pubTime":"2024-11-15 10:15","pubTimestamp":1731636908,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences, Inc. Class A (SGMT) has received a new Buy rating, initiated by TD Cowen analyst, Ritu Baral. Ritu Baral has given her Buy rat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/sagimet-biosciences-inc-strategic-advancements-and-financial-robustness-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/sagimet-biosciences-inc-strategic-advancements-and-financial-robustness-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"gpt_icon":0},{"id":"2483457808","title":"Sagimet Biosciences Q3 EPS $(0.45) Misses $(0.42) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483457808","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483457808?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:32","pubTimestamp":1731591156,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.42) by 7.14 percent. This is a 28.57 percent decrease over losses of $(0.35) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41971495/sagimet-biosciences-q3-eps-0-45-misses-0-42-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Sagimet Biosciences Q3 EPS $(0.45) Misses $(0.42) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2483387725","title":"Sagimet Biosciences Inc: Anticipated Cash Runway Through 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2483387725","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483387725?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUACBJSK5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2483877540","title":"Press Release: Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483877540","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483877540?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"Denifanstat received Breakthrough Therapy designation from FDA for MASH. Successful completion of end-of-Phase 2 interactions with FDA on the development of denifanstat for MASH; Phase 3 program initiation expected by end of 2024. Anticipated cash runway through 2025, with cash, cash equivalents and marketable securities totaling $170.0 million as of September 30, 2024. \"As we approach the end of 2024, the Sagimet team remains focused on advancing denifanstat towards a pivotal Phase 3 program in MASH,\" said David Happel, Chief Executive Officer of Sagimet. \"The publication of our Phase 2b FASCINATE-2 study results in a highly regarded Lancet journal highlighted denifanstat's strong efficacy and tolerability data and its highly differentiated mechanism of action which enables denifanstat to improve the key drivers of MASH: fat accumulation, inflammation, and fibrosis. In addition, we are proud to have recently received Breakthrough Therapy designation for denifanstat in MASH from the FD","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sagimet.com","stockEarnings":[{"period":"1week","weight":0.2378},{"period":"1month","weight":0.0922},{"period":"3month","weight":0.3389},{"period":"6month","weight":0.7034},{"period":"1year","weight":0.0879},{"period":"ytd","weight":0.2378}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":-0.0316},{"period":"3month","weight":0.0199},{"period":"6month","weight":0.0578},{"period":"1year","weight":0.2403},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.","exchange":"NASDAQ","name":"Sagimet Biosciences Inc.","nameEN":"Sagimet Biosciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sagimet Biosciences Inc.,SGMT,Sagimet Biosciences Inc.股票,Sagimet Biosciences Inc.股票老虎,Sagimet Biosciences Inc.股票老虎国际,Sagimet Biosciences Inc.行情,Sagimet Biosciences Inc.股票行情,Sagimet Biosciences Inc.股价,Sagimet Biosciences Inc.股市,Sagimet Biosciences Inc.股票价格,Sagimet Biosciences Inc.股票交易,Sagimet Biosciences Inc.股票购买,Sagimet Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction